📋 Key Information Summary
- Subfertility is defined as failure to conceive after 12 months of regular unprotected intercourse (6 months if female partner ≥35 years); affects approximately 1 in 6 Australian couples.
- Aetiology is shared equally: ~30% female factors, ~30% male factors, ~20% combined, and ~20% unexplained; always investigate both partners simultaneously.
- Ovulatory dysfunction (including PCOS) accounts for approximately 25–30% of female subfertility and is the most treatable cause.
- Male factor investigation begins with at least two semen analyses performed 4–12 weeks apart; azoospermia or severe oligospermia warrants urgent urology referral.
- PCOS diagnosis follows the Rotterdam criteria (2 of 3: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound); affects 12–21% of Australian women of reproductive age.
- First-line ovulation induction for anovulatory PCOS is letrozole (2.5–7.5 mg PO days 2–6) — superior live birth rates versus clomiphene per international RCTs; clomiphene remains an alternative.
- Tubal patency should be assessed with hysterosalpingography (HSG) or laparoscopy with dye; tubal factor accounts for ~20% of female subfertility.
- Ovarian reserve testing (AMH, antral follicle count) guides ART stimulation protocols but has limited predictive value for natural conception.
- Assisted reproductive technology (ART) — IVF/ICSI — is indicated for tubal factor, severe male factor, endometriosis-associated subfertility, failed ovulation induction, and unexplained subfertility after ≥12 months expectant management.
- Lifestyle modification (weight loss of 5–10% if BMI >30, smoking cessation, alcohol reduction, folic acid 400–500 µg daily) improves natural and treatment-conceived pregnancy rates.
- Aboriginal and Torres Strait Islander Australians have higher rates of sexually transmitted infections (chlamydia, gonorrhoea) causing tubal disease, later presentation, and barriers to ART access — proactive screening and culturally safe referral are essential.
- Safety alert: Clomiphene should not exceed 6 ovulatory cycles or 12 months total; prolonged use increases ovarian hyperstimulation and theoretical ovarian cancer risk.
Introduction & Australian Epidemiology
Subfertility — defined as the inability to conceive after 12 months of regular unprotected sexual intercourse (or 6 months when the female partner is aged ≥35 years) — is a common presentation in Australian general practice, affecting an estimated one in six couples during their reproductive years. The Australian Institute of Health and Welfare (AIHW) reports that approximately 38,000 ART treatment cycles are performed annually across >90 accredited fertility centres nationwide, reflecting both the burden of disease and the increasing demand for assisted conception.
The aetiology of subfertility is broadly distributed: female factors account for approximately 30%, male factors for 30%, combined factors for 20%, and a further 20% of couples are classified as having unexplained subfertility after comprehensive investigation. Importantly, both partners should be assessed concurrently, as delay in identifying male factor or tubal disease can prolong time to conception significantly.
Australian data from the Fertility Society of Australia and New Zealand (FSANZ) indicate that the median age of women accessing ART has risen to 36 years, reflecting broader societal trends toward delayed childbearing. Advanced maternal age (>35 years) is independently associated with reduced oocyte quality, diminished ovarian reserve, and increased miscarriage rates, making timely investigation and referral essential.
This guideline provides a structured approach to the investigation and management of the subfertile couple in the Australian primary care setting, with reference to Therapeutic Guidelines (eTG), the Royal Australian College of General Practitioners (RACGP) Red Book, Fertility Society of Australia and New Zealand (FSANZ) consensus statements, and relevant international evidence.
Key Australian statistics: ~1 in 6 couples experience subfertility · ~38,000 ART cycles/year · Median ART maternal age 36 years · PCOS prevalence 12–21% · Male factor contributes to ~50% of cases (sole or combined).
Causes of Subfertility — Male & Female Factors
A systematic approach to identifying the cause of subfertility requires assessment of both partners. The major aetiological categories are outlined below.
Female Factors
| Category | Proportion | Key Causes | Key Points |
|---|---|---|---|
| Ovulatory dysfunction | ~25–30% | PCOS, hypothalamic amenorrhoea, hyperprolactinaemia, thyroid dysfunction, premature ovarian insufficiency (POI) | Most treatable cause; ovulation induction has high success rates |
| Tubal/peritoneal | ~20% | Pelvic inflammatory disease (PID), chlamydia/gonorrhoea, endometriosis, previous ectopic, adhesions | STI screening essential; Aboriginal and Torres Strait Islander women at higher risk of tubal disease |
| Uterine | ~5–10% | Submucosal fibroids, endometrial polyps, Asherman syndrome, congenital uterine anomalies | Transvaginal ultrasound ± saline infusion sonography (SIS) for assessment |
| Diminished ovarian reserve | Varies with age | Advanced maternal age, previous ovarian surgery, chemotherapy/radiotherapy, FMR1 premutation | AMH and antral follicle count (AFC) guide prognosis and ART protocols |
| Cervical | Rare | Cervical stenosis, hostile mucus (historical concept) | Largely superseded by IUI/IVF as treatment |
Male Factors
| Category | Key Causes | Key Points |
|---|---|---|
| Impaired spermatogenesis | Varicocele, cryptorchidism, testicular tumour, genetic (Klinefelter 47,XXY; Y-chromosome microdeletions), chemotherapy/radiotherapy, mumps orchitis | Most common male factor; may present as oligo-, astheno-, or teratozoospermia |
| Obstructive | Congenital bilateral absence of vas deferens (CBAVD — CFTR mutations), vasectomy, ejaculatory duct obstruction | Azoospermia with normal FSH suggests obstruction; surgical sperm retrieval may be feasible |
| Endocrine | Hypogonadotrophic hypogonadism, hyperprolactinaemia, exogenous testosterone/anabolic steroid use | Exogenous testosterone is an increasingly common reversible cause in Australian men |
| Ejaculatory/sexual | Erectile dysfunction, retrograde ejaculation, premature ejaculation, anejaculation | Address psychogenic and organic causes; sperm retrieval options available |
| Idiopathic | No identifiable cause | ~30–40% of abnormal semen analyses; empirical treatment limited |
Exogenous testosterone use: Exogenous testosterone (including testosterone replacement therapy and anabolic steroids) suppresses the hypothalamic-pituitary-gonadal axis causing azoospermia. Cessation and gonadotrophin therapy (hCG ± FSH) may restore spermatogenesis, but recovery can take 6–24 months. Always enquire about testosterone use in subfertile males.
Combined & Unexplained Factors
Approximately 20% of couples have contributions from both male and female factors, and a further 20% will have no identifiable cause after comprehensive investigation (unexplained subfertility). Unexplained subfertility is a diagnosis of exclusion and does not imply the absence of pathology — rather, it reflects the limitations of current investigation. Expectant management with lifestyle optimisation is appropriate for 6–12 months before considering empirical treatment or ART.
Investigations
Investigation of the subfertile couple should commence after 12 months of attempting conception (6 months if female age ≥35 years, or if history suggests a specific risk factor such as amenorrhoea or previous pelvic surgery). Both partners should be assessed concurrently.
Semen Analysis
Semen analysis is the cornerstone of male subfertility investigation. The WHO 2021 reference ranges (6th edition) should be used for interpretation.
| Parameter | WHO 2021 Lower Reference Limit (5th centile) |
|---|---|
| Volume | ≥1.4 mL |
| Concentration | ≥16 million/mL |
| Total sperm number | ≥39 million per ejaculate |
| Progressive motility | ≥30% |
| Total motility | ≥42% |
| Normal morphology | ≥4% (strict Kruger criteria) |
Key practice points for semen analysis:
- Abstinence period of 2–7 days (ideally 3–5 days) before collection.
- At least two samples, 4–12 weeks apart, as significant intra-individual variability exists.
- Performed at an accredited NATA/RCPA laboratory (most Australian IVF labs and pathology providers).
- If abnormal, proceed to hormonal evaluation (FSH, LH, testosterone, prolactin) and consider scrotal ultrasound.
- Azoospermia requires urgent referral to a reproductive urologist or fertility specialist.
Ovulatory Assessment
Confirmation of ovulation is a fundamental step in female subfertility investigation.
Essential
Mid-luteal serum progesterone
Measured 7 days before expected period (day 21 of a 28-day cycle; adjust for cycle length). A level >25 nmol/L is strongly suggestive of ovulation. Levels of 15–25 nmol/L are equivocal; <15 nmol/L suggests anovulation. MBS Item 66748.
Available
Urinary LH ovulation predictor kits (OPKs)
Commercially available (e.g., Clearblue®). Useful for timing intercourse or insemination but confirmatory serum progesterone is preferred for diagnostic purposes.
Available
Basal body temperature (BBT) charting
Biphasic pattern supports ovulation; low sensitivity and specificity; largely superseded by serum progesterone.
Available
Transvaginal ultrasound follicular tracking
Serial scans from day 8–10 to observe dominant follicle growth and collapse (suggesting ovulation). Resource-intensive; primarily used in conjunction with ovulation induction or IUI cycles. MBS Item 55054/55062.
Female Hormonal & Reserve Assessment
Essential
Day 2–5 FSH, LH, oestradiol
Elevated FSH (>10 IU/L) or low oestradiol suggests diminished ovarian reserve. Elevated LH:FSH ratio (>2:1) is suggestive of PCOS. MBS Item 66744.
Available
Anti-Müllerian hormone (AMH)
Can be measured on any day of the cycle. Reflects ovarian reserve (not fertility per se). Guides ART stimulation protocol selection. Low AMH (<6 pmol/L) indicates diminished reserve. High AMH (>40 pmol/L) suggestive of PCOS. Not covered by MBS — out-of-pocket ~–100.
Essential
Thyroid function (TSH, ± fT4)
Both overt and subclinical hypothyroidism (TSH >2.5 mIU/L in some fertility protocols) and hyperthyroidism impair fertility. MBS Item 66717.
Essential
Prolactin
Hyperprolactinaemia causes anovulation. Measure if oligo/amenorrhoea present. Exclude macroprolactinoma if markedly elevated. MBS Item 66746.
Essential
Rubella immunity (IgG)
Standard pre-conception screening; offer MMR if non-immune (avoid conception for 28 days post-vaccination). MBS Item 69498.
Essential
Chlamydia & gonorrhoea screening (NAAT)
Untreated chlamydia is a leading cause of tubal factor subfertility in Australia. Test both partners. Self-collected vaginal swabs acceptable. MBS Item 69399.
Tubal Patency Assessment
Essential
Hysterosalpingography (HSG)
First-line assessment of tubal patency. Radiographic contrast injected via cervix; identifies tubal occlusion and uterine cavity abnormalities. Sensitivity 65%, specificity 80% for tubal pathology. Mildly therapeutic — post-HSG pregnancy rates modestly increased. MBS Item 57504.
Specialist
Laparoscopy with chromotubation (dye test)
Gold standard for tubal assessment; also evaluates endometriosis and adhesions. Indicated when HSG is inconclusive, endometriosis is suspected, or concurrent therapeutic intervention is planned. Requires general anaesthesia.
Available
HyCoSy (hysterosalpingo-contrast-sonography)
Ultrasound-based alternative to HSG using saline/contrast. No radiation exposure; increasingly available in Australian fertility centres. Comparable accuracy to HSG.
Male Hormonal Evaluation
Indicated when semen analysis is abnormal (particularly oligospermia or azoospermia).
Essential
FSH, LH, total testosterone, prolactin
Elevated FSH with azoospermia suggests testicular failure (non-obstructive). Normal FSH with azoospermia suggests obstruction. Low testosterone with low/normal FSH/LH suggests hypogonadotrophic hypogonadism (consider MRI pituitary). MBS Item 66744.
Available
Scrotal ultrasound
Identifies varicocele, testicular masses, testicular volume. MBS Item 55300.
Specialist
Genetic testing
Karyotype (Klinefelter syndrome), Y-chromosome microdeletion analysis, CFTR mutation screen (CBAVD). Indicated for severe oligospermia (<5 million/mL) or azoospermia.
PCOS & Ovulatory Dysfunction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age, with an estimated prevalence of 12–21% in Australian women depending on the diagnostic criteria applied. It is the leading cause of anovulatory subfertility and is associated with metabolic, psychological, and reproductive morbidity.
Diagnosis — Rotterdam Criteria (2003)
PCOS is diagnosed when at least 2 of the following 3 criteria are met (after exclusion of other aetiologies such as thyroid dysfunction, congenital adrenal hyperplasia, Cushing syndrome, hyperprolactinaemia, and androgen-secreting tumours):
1
Oligo-anovulation
Cycle length >35 days, <8 cycles per year, or amenorrhoea. May present with irregular menstrual bleeding.
2
Clinical and/or biochemical hyperandrogenism
Hirsutism (modified Ferriman-Gallwey score ≥4–6), acne, androgenic alopecia, or elevated serum total/free testosterone, DHEAS, androstenedione.
3
Polycystic ovarian morphology on ultrasound
≥20 follicles per ovary (2–9 mm) and/or ovarian volume >10 mL on transvaginal ultrasound. Note: not required for diagnosis if criteria 1 and 2 are met; should not be used in adolescents within 8 years of menarche.
Do not diagnose PCOS in adolescents within the first 8 years post-menarche based solely on ultrasound findings, as polycystic ovarian morphology is common in normal adolescents. Diagnosis in this group requires both oligo-anovulation and hyperandrogenism.
PCOS Phenotypes
| Phenotype | Features | Fertility Implications |
|---|---|---|
| A (Classic) | Hyperandrogenism + ovulatory dysfunction + PCO morphology | Most significant metabolic and reproductive impact; highest AMH |
| B (Classic) | Hyperandrogenism + ovulatory dysfunction | Anovulatory subfertility common; good response to ovulation induction |
| C (Ovulatory) | Hyperandrogenism + PCO morphology | May ovulate regularly; subfertility may be multifactorial |
| D (Non-hyperandrogenic) | Ovulatory dysfunction + PCO morphology | Milder metabolic risk; ovulation induction effective |
Other Causes of Ovulatory Dysfunction
| Cause | Mechanism | Investigation | Management |
|---|---|---|---|
| Hypothalamic amenorrhoea | Functional suppression of GnRH (excessive exercise, low BMI, stress, eating disorders) | Low FSH, LH, oestradiol; exclude other causes with MRI pituitary | Lifestyle modification, weight restoration, pulsatile GnRH (specialist), or gonadotrophin therapy for ovulation induction |
| Hyperprolactinaemia | Prolactin suppresses GnRH pulsatility | Serum prolactin; MRI pituitary if >1,000 mIU/L or associated features | Cabergoline (0.25–1 mg PO twice weekly) — first-line dopamine agonist. PBS Authority Required. |
| Thyroid dysfunction | Both hypo- and hyperthyroidism disrupt ovulation | TSH, fT4, fT3 | Correct thyroid dysfunction; levothyroxine for hypothyroidism (aim TSH <2.5 mIU/L for conception) |
| Premature ovarian insufficiency (POI) | Ovarian failure before age 40 (autoimmune, iatrogenic, genetic including FMR1 premutation) | FSH >40 IU/L on 2 occasions ≥4 weeks apart; karyotype; FMR1; autoimmune screen; AMH | Fertility specialist referral; donor oocyte IVF usually required; HRT for symptom management |
Metabolic Screening in PCOS
All women with PCOS should undergo metabolic screening given the increased risks of type 2 diabetes, dyslipidaemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD).
- Fasting glucose and HbA1c (or 75 g OGTT — preferred if BMI >30 or other risk factors)
- Fasting lipid profile
- Blood pressure measurement
- BMI and waist circumference
- Repeat screening every 1–3 years depending on risk factors
Management Principles & ART
General Principles
Lifestyle modification is the foundation of subfertility management and should be addressed before or alongside any pharmacological or procedural intervention. A weight loss of just 5–10% in overweight/obese women can restore ovulatory cycles and significantly improve both spontaneous and treatment-conceived pregnancy rates.
- Weight management: BMI 18.5–25 kg/m² optimises fertility outcomes; referral to a dietitian is recommended.
- Folic acid: 400–500 µg daily (5 mg if BMI >30, diabetes, anti-epileptic medication, or previous neural tube defect pregnancy).
- Smoking cessation: Smoking reduces fertility in both partners; offer NRT and support (freely available through Quitline 13 7848 and Quit programmes). PBS-listed options include varenicline (Champix® — when available) and nicotine replacement therapy.
- Alcohol: Advise cessation for women attempting conception and moderation for men (≤10 standard drinks per week).
- Caffeine: Limit to <200 mg/day (~1–2 cups of coffee) for women.
- Exercise: Moderate regular exercise (150 min/week); avoid excessive high-intensity exercise in women with low BMI/hypothalamic amenorrhoea.
- Mental health: Subfertility is associated with significant psychological distress; screen for anxiety and depression; offer counselling and peer support (e.g., Access Australia, Emerging Proud).
Ovulation Induction
Indicated for anovulatory subfertility (most commonly WHO Group II — PCOS). Ovulatory women with unexplained subfertility should not receive empirical ovulation induction (limited benefit, increased multiple pregnancy risk).
Letrozole
Femara® · Novartis · Aromatase inhibitor
Adult dose
2.5–7.5 mg PO daily, days 2–6 of cycle (or days 3–7). Start at 2.5 mg; increase by 2.5 mg per cycle if no ovulation (max 7.5 mg).
Mechanism
Reduces oestrogen-mediated negative feedback → increases endogenous FSH → stimulates folliculogenesis. Lower multiple pregnancy rate than clomiphene.
Duration
Up to 6 ovulatory cycles. If no pregnancy after 6 ovulatory cycles, consider referral for gonadotrophin therapy or IVF.
Key side effects
Hot flushes, fatigue, dizziness. Contraindicated in pregnancy (theoretical teratogenicity — avoid in luteal phase).
Renal adjustment
No specific adjustment; use with caution in severe renal impairment (eGFR <30).
PBS status
⚠ Not PBS for ovulation induction (off-label use) — ~–30 per cycle (private prescription). Subsidised for breast cancer indication.
Clomiphene citrate
Clomid® · Sanofi-Aventis · Selective oestrogen receptor modulator (SERM)
Adult dose
50 mg PO daily, days 2–6 of cycle. Increase to 100 mg then 150 mg if no ovulation at previous dose.
Mechanism
Blocks oestrogen receptors at hypothalamus → reduces negative feedback → increases GnRH → FSH release. Anti-oestrogenic effect on endometrium and cervical mucus.
Duration
Maximum 6 ovulatory cycles (not 6 attempts — ovulatory cycles specifically). Do not exceed 12 months total use.
Key side effects
Multiple pregnancy rate ~7–8% (predominantly twins); ovarian hyperstimulation (rare at standard doses); visual disturbances (discontinue if occur); hot flushes; anti-oestrogenic endometrial thinning.
Renal / Hepatic
No specific adjustment. Avoid in hepatic impairment.
PBS status
✔ PBS General Benefit — Available on PBS for ovulation induction.
Metformin
Diabex® / Glucophage® · Various · Biguanide
Adult dose
500 mg PO BD with meals, titrate to 1,000–1,500 mg BD over 2–4 weeks (max 2,550 mg/day).
Role in PCOS
Improves insulin sensitivity → reduces hyperinsulinaemia → may restore ovulation. Second-line or adjunct to letrozole/clomiphene. Most effective in obese PCOS women. Can be combined with clomiphene in resistant cases.
Duration
Continued through first trimester in some protocols (reduces miscarriage risk in PCOS); discuss with fertility specialist.
Key side effects
GI (nausea, diarrhoea, bloating) — mitigated by slow titration. Lactic acidosis (rare; avoid if eGFR <30). Vitamin B12 deficiency with long-term use.
Renal adjustment
eGFR 30–45: reduce dose (max 1,000 mg/day). eGFR <30: contraindicated.
PBS status
✔ PBS General Benefit (for type 2 diabetes). Off-label for PCOS — private prescription ~–15/month.
Exogenous gonadotrophins (FSH injections) for ovulation induction in PCOS should only be initiated by a fertility specialist due to the significant risk of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy. Low-dose step-up protocols are standard practice.
Intrauterine Insemination (IUI)
IUI involves placement of prepared sperm directly into the uterine cavity, timed to ovulation. It may be performed in natural cycles or with mild ovarian stimulation (clomiphene/letrozole or low-dose FSH).
- Indications: Mild male factor, cervical factor, unexplained subfertility, mild endometriosis, anejaculation/retrograde ejaculation (with sperm retrieval).
- Success rate: ~8–15% per cycle; cumulative pregnancy rate ~30–40% over 3–4 cycles.
- Not indicated for: Severe male factor (count <5 million), bilateral tubal occlusion, severe endometriosis — these require IVF/ICSI.
Assisted Reproductive Technology (ART)
ART encompasses IVF (in vitro fertilisation) and ICSI (intracytoplasmic sperm injection) and is indicated when simpler interventions have failed or when the clinical scenario warrants direct progression to ART.
Indications for ART Referral
Absolute Indications
- Bilateral tubal occlusion/absence
- Severe male factor (count <5 million, <1% normal morphology, azoospermia requiring surgical retrieval)
- Premature ovarian insufficiency (donor oocyte)
- Genetic conditions requiring PGT-M (preimplantation genetic testing for monogenic disorders)
Relative Indications
- Failed ovulation induction (3–6 ovulatory cycles without pregnancy)
- Endometriosis-associated subfertility (moderate–severe)
- Unexplained subfertility after ≥12 months expectant management
- Advanced maternal age (>37 years) — lower threshold for ART
- Diminished ovarian reserve (low AMH/AFC)
ART Treatment Pathway
Step 1
Ovarian stimulation — Daily subcutaneous FSH injections (Gonal-f®, Puregon®) with GnRH antagonist (Cetrotide®, Orgalutran®) or agonist downregulation protocol. Monitoring with serial serum oestradiol and transvaginal ultrasound.
Step 2
Trigger injection — hCG (Ovidrel® 250 µg SC, or Pregnyl® 5,000–10,000 IU IM) when ≥3 follicles reach ≥17 mm. Alternatively, GnRH agonist trigger (Lucrin®) in high-risk OHSS protocols.
Step 3
Oocyte retrieval — Transvaginal ultrasound-guided aspiration 34–36 hours post-trigger, under conscious sedation (day procedure).
Step 4
Fertilisation — Conventional IVF (oocytes incubated with prepared sperm) or ICSI (single sperm injected into each mature oocyte — for male factor or prior IVF fertilisation failure).
Step 5
Embryo culture — Extended culture to blastocyst (day 5–6) preferred when sufficient embryos; allows better embryo selection. PGT-A available for aneuploidy screening (advanced maternal age, recurrent miscarriage).
Step 6
Embryo transfer — Fresh transfer of 1 blastocyst (single embryo transfer is standard Australian practice to minimise multiple pregnancy) or freeze-all strategy with subsequent frozen embryo transfer (FET) cycle.
Step 7
Luteal support — Progesterone (Crinone® 8% vaginal gel daily, or Utrogestan® 200 mg vaginal/PO TDS, or progesterone pessaries) from day of oocyte retrieval until 10–12 weeks gestation if pregnant.
Key ART Medications — Australian Context
Follitropin alfa / beta (recombinant FSH)
Gonal-f® / Puregon® · Gonadotrophin
Adult dose
150–450 IU SC daily, individualised to ovarian reserve (AMH/AFC). Low-dose step-up for PCOS (start 75–150 IU).
PBS status
🔒 Authority Required — ART programme only · Subsidised through approved ART centres. Out-of-pocket ~ ,500–4,000 per cycle depending on dose.
Cetrorelix / Ganirelix (GnRH antagonists)
Cetrotide® / Orgalutran® · GnRH antagonist
Adult dose
0.25 mg SC daily, started when lead follicle reaches ~13–14 mm or on stimulation day 5–6.
PBS status
🔒 Authority Required — ART programme only
Progesterone (luteal support)
Crinone® 8% gel · Utrogestan® 200 mg capsules
Adult dose
Crinone® 8%: 1 applicator (90 mg) vaginal daily. Utrogestan®: 200 mg vaginal or PO TDS. Continue until 10–12 weeks gestation if pregnant.
PBS status
⚠ Restricted Benefit — Crinone subsidised for ART luteal support. Utrogestan varies by indication.
ICSI vs Conventional IVF
| Feature | Conventional IVF | ICSI |
|---|---|---|
| Indication | Tubal factor, unexplained, mild endometriosis, ovulatory dysfunction | Severe male factor, prior fertilisation failure, surgically retrieved sperm, PGT cycles |
| Fertilisation rate | ~60–70% per oocyte | ~70–80% per oocyte |
| Live birth rate | Comparable to ICSI when no male factor | Comparable to IVF; superior when male factor present |
| Cost | Lower laboratory component | Additional ~0–1,000 ICSI fee |
Male Factor Management
- Empirical antioxidant therapy (e.g., CoQ10 200 mg, vitamin C 1,000 mg, vitamin E 400 IU, zinc 25 mg daily): limited evidence; may modestly improve sperm parameters. Not PBS-listed for this indication.
- Varicocele repair: Indicated if clinically significant grade II–III varicocele with abnormal semen parameters; may improve sperm quality. Refer to urologist.
- Gonadotrophin therapy (hCG ± FSH) for hypogonadotrophic hypogonadism or testosterone cessation: can restore spermatogenesis. Specialist-initiated.
- Surgical sperm retrieval (TESE/micro-TESE): for obstructive or non-obstructive azoospermia in conjunction with ICSI.
- Sperm cryopreservation: Recommended prior to chemotherapy, radiotherapy, or vasectomy. Available at most fertility centres; MBS item may apply.
Monitoring During Treatment
- During ovulation induction: Mid-luteal progesterone (confirm ovulation); transvaginal ultrasound for follicle tracking (particularly with gonadotrophins — mandatory to monitor for OHSS).
- During ART cycles: Serial serum oestradiol and transvaginal ultrasound every 1–3 days during stimulation; serum β-hCG 14 days post-transfer.
- OHSS monitoring: Weight, abdominal girth, urine output, haematocrit. Severe OHSS requires hospital admission.
- Multiple pregnancy risk: Single embryo transfer (SET) is the standard of care in Australia (FSANZ guidelines) to minimise higher-order multiples.
ART Success Rates — Australian Data (FSANZ 2022)
| Female Age | Live Birth Rate per Embryo Transfer (Fresh) | Live Birth Rate per Embryo Transfer (Frozen) |
|---|---|---|
| <30 years | ~28–32% | ~32–36% |
| 30–34 years | ~25–30% | ~30–34% |
| 35–39 years | ~18–24% | ~22–28% |
| 40–44 years | ~8–14% | ~12–18% |
| ≥45 years | ~2–5% | ~5–8% |
Data source: Fertility Society of Australia and New Zealand (FSANZ) Annual Report 2022. Rates are approximate and vary by clinic, cause, and use of PGT.
Special Populations
Paediatric & Adolescent
PCOS can present in adolescence with oligomenorrhoea and acne/hirsutism, but diagnosis requires both oligo-anovulation AND hyperandrogenism — ultrasound alone is insufficient within 8 years of menarche.
Adolescents with eating disorders or excessive exercise should be counselled about fertility implications of hypothalamic amenorrhoea.
Fertility preservation (oocyte/ovarian tissue cryopreservation) should be discussed before gonadotoxic chemotherapy or radiotherapy in adolescent cancer patients.
Pregnancy
Discontinue letrozole, clomiphene, and metformin (per specialist advice) once pregnancy confirmed. Teratogenicity risk for letrozole is theoretical (Category D) but data are reassuring when stopped at conception.
First-trimester viability ultrasound at 7–8 weeks. Multiple pregnancy screening if ovulation induction or IUI with stimulation was used.
ART pregnancies carry slightly increased risks of preterm birth, low birth weight, placenta praevia, and hypertensive disorders — enhanced antenatal surveillance recommended.
Advanced Paternal Age
Paternal age >45 years is associated with decreased sperm quality, longer time to conception, increased miscarriage risk, and modestly elevated risk of neurodevelopmental conditions in offspring.
Counselling regarding time-to-conception expectations and consideration of earlier ART referral when combined with advanced maternal age.
Renal Impairment
Metformin: contraindicated if eGFR <30; reduce dose if eGFR 30–45.
NSAIDs (used for pain in endometriosis): avoid in severe CKD.
Pregnancy in women with CKD requires multidisciplinary management (nephrologist, obstetrician, fertility specialist).
Hepatic Impairment
Metformin: use with caution in hepatic impairment; avoid in significant liver disease (lactic acidosis risk).
Clomiphene: avoid in hepatic impairment or active liver disease.
PCOS with NAFLD — consider hepatology input; pregnancy may exacerbate intrahepatic cholestasis in susceptible individuals.
Immunocompromised
HIV-positive individuals: fertility management should be coordinated with infectious disease specialist; sperm washing or PrEP for serodiscordant couples; ART access should not be denied.
Women on immunosuppressants (e.g., methotrexate, mycophenolate): switch to pregnancy-safe agents (e.g., azathioprine, hydroxychloroquine) before conception — rheumatology/immunology input essential.
Autoimmune POI: screen for associated autoimmune conditions (Addison disease, thyroid disease, coeliac disease).
Aboriginal and Torres Strait Islander Health Considerations
📚 References
- 1. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379. doi:10.1016/j.fertnstert.2018.05.008
- 2. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 6th ed. Geneva: WHO; 2021.
- 3. Fertility Society of Australia and New Zealand (FSANZ). Australia and New Zealand Assisted Reproduction Database (ANZARD) — Annual Report 2022. Melbourne: FSANZ; 2023.
- 4. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129. doi:10.1056/NEJMoa1313517
- 5. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice (Red Book). 9th ed. Melbourne: RACGP; 2018.
- 6. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines: Antenatal Care — Module A. Canberra: Australian Government Department of Health; 2020.
- 7. ESHRE Guideline Group on Female Fertility. ESHRE guideline: female fertility management. Hum Reprod Open. 2024;2024(1):hoae001. doi:10.1093/hropen/hoae001
- 8. Nankervis A, McIntyre HD, Moses R, et al. ADIPS Consensus Guidelines for the Testing and Diagnosis of Gestational Diabetes Mellitus in Australia and New Zealand. ADIPS; 2014. (Referenced for metabolic screening context in PCOS.)
- 9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023. (STI and reproductive health data.)
- 10. NICE Clinical Guideline [CG156]. Fertility Problems: Assessment and Treatment. National Institute for Health and Care Excellence; 2013 (updated 2024).
- 11. Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44–e50.
- 12. European Association of Urology (EAU). EAU Guidelines on Sexual and Reproductive Health — Male Infertility. Arnhem: EAU; 2024.
- 13. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697. doi:10.1016/S0140-6736(07)61345-2
- 14. Hart RJ, Doherty DA, McLachlan RI, et al. Testicular function in a birth cohort of young men. Hum Reprod. 2015;30(12):2713–2724. (Australian Normative Study.)
- 15. Department of Health and Aged Care, Australian Government. Medicare Benefits Schedule (MBS) — Pathology and Diagnostic Imaging Items. Canberra: Commonwealth of Australia; 2024.